Introduction
The role of alloantibodies, especially HLA antibodies, in solid-organ transplant recipients both before and after transplantation has progressively regained attention for the last two decades.
Traditionally, HLA antibodies have been considered a strong barrier for sensitized recipients to access transplantation due to their ability to induce hyperacute rejection [1] . Sensitization can occur due to pregnancy, blood transfusions, or previous transplants. The number of transfusions has decreased with the use of erythropoiesis stimulating agents, thus potentially decreasing the number of sensitized patients.
However, the rate of retransplantation is increasing, as long-term graft survival improvement does not yet parallel improvement in short-term survival [2] [3] [4] . Besides, newer and more sensitive solid-phase assays are able to identify HLA antibodies otherwise undetected by cell-based techniques. Although still under intense debate [5] , these tests reveal that there is a higher percentage of sensitized transplant recipients than previously identified. These transplant recipients seem to be at higher risk for antibody-mediated damage, which impacts early survival but also diminishes medium to long-term graft survival [6] . Huge efforts are being made to try to identify what amount, type or quality of HLA antibodies should preclude transplantation [6] [7] [8] [9] .
Additionally, post-transplant HLA donor-specific anti-HLA antibodies (DSA) are increasingly recognized as risk factors for kidney, heart, lung, pancreas and liver allograft loss [10] [11] [12] [13] [14] [15] [16] [17] [18] . Intragraft donor-specific antibodies have been obtained from biopsies in transplant recipients with circulating DSA and microvascular inflammation, supporting their pathogenic role in graft damage [19] . Detection of DSA in serum, together with typical histological changes of microvascular damage leads to the diagnosis of antibody-mediated rejection [20] [21] [22] . This has arisen as a major pathological entity responsible for early graft loss, mostly in sensitized patients, and for over 50% long-term censured graft loss as a consequence of chronic inflammation and progressive tissue destruction [23] [24] [25] .
Important questions, such as whether the detection of different levels or distinct avidity of HLA DSA can predict specific graft outcome are not answered yet. Furthermore, it is unclear whether the absence of DSA reflects absence of a B cell response to the donor, active tolerance or a masked immune response by binding of DSA to the graft [26] .
Recent data suggest that besides their role in antibody production, B cells participate in antibodyindependent responses, potentially leading to allograft rejection or allograft tolerance [23, 27, 28] . The transplant community has therefore widened their focus to B cells as important regulators of alloimmune responses by their ability to induce donor-specific damage through DSA [11] [12] [13] [14] 23, 29] .
Several tools are currently available to study HLA alloantibodies and general B-cell properties, but assays to study alloantigen specific B-cells are still a matter of research. Studies on B cells in transplantation have been hampered by the heterogeneity of subsets that may participate in responses to the graft and antibody production and extremely low frequencies of peripheral antigen-specific B cells.
Here, we present an overview of the existent assays and techniques intended to describe characteristics of peripheral B cells and the currently available HLA specific B cell functional assays that may allow for monitoring the humoral alloimmune response in transplant recipients. Although the main focus of this review is on the kidney transplant setting, the techniques described herein will be applicable to other transplant settings as well.
B cell immunophenotyping

B cell subsets
In the 70s, B and T cells were first identified as two different lymphocyte populations [30] . A first modern classification of five B cell subpopulations came from studies on tonsillar B cells considering surface expression of IgD and CD38 [33] . This so called Bm1-Bm5 classification includes [34] (Fig. 1A Human B cell subsets can alternatively be defined by their surface expression levels of CD24 and CD38 (naïve, memory and transitional B cells) [39] . Naïve B cells are CD24 dim CD38 dim , whereas memory B cells are CD24 hi CD38 − . Transitional B cells are characterized by high expression levels of CD24 and CD38, which can be supplemented by the addition of CD27 negativity and CD24 positivity.
The way how subsets defined by one classification scheme relate to those subsets defined by other scheme is not often clear. In an effort to combine the above classifications, Sanz et al. worked on six different 10-color flow cytometry panels according to the phenotypic complexity of B cells with antibodies against CD3, CD19, IgD, IgM, IgG, CD10, CD24, CD27, CD38, CD1c, CD45 (B220) and
FcRH4. The analysis of additional surface markers permits the identification of additional subpopulations of memory cells within both CD27 + and CD27 − cells [32] . Table 1 shows a simplified scheme adapted from this classification emphasizing the combination of IgD, CD27 and CD38 (Table 1) . leukocyte subsets resulted in a high concordance across multiple international sites [41] (Fig. 3) . In summary, characterization of B cells is getting more complex as the knowledge of phenotypes, functionality and clinical engagement increases. It is therefore pivotal to obtain standardized panels that may be reproducible in different laboratories. For the transplant setting, efforts are now being made to harmonize panels and protocols, which should result in a uniform data collection and analysis approach.
B cell subtypes and allograft rejection
The role of B cells in allograft rejection, besides antibody production, is becoming increasingly obvious [42] , but their specific role in rejection is still not clear. In the rejection process, B cells may participate through antigen presentation, cytokine production, immune regulation and differentiation into alloantibody-producing plasma cells [43] . The fact that B cells can be involved in antigen presentation during acute cellular rejection has been shown in animal models [44] . Several clinical studies have shown CD20 + B cell infiltrates in kidney biopsy samples from patients with acute rejection [45] [46] [47] [48] [49] . The absence of C4d deposits in peritubular capillaries and circulating antibodies suggested that B cells may have had an antibody-independent function, such as antigen presentation [45] . Additionally, intragraft B cells clusters have been detected in animal models of chronic rejection and explanted transplants lost for chronic rejection [50] . These clusters were the site of intense proliferation and production of antibodies directed against the donor [51, 52] .
Unlike data on B cell infiltrates in rejecting kidneys, there is not much information about the peripheral B cell subset distribution in kidney transplant recipients [53] . Kamburova et al. has described the kinetics of peripheral B cells according to the Bm1-Bm5 classification in a cohort of kidney transplant recipients on standard triple immunosuppressive therapy, as well as a group of patients receiving rituximab induction therapy [54] . Patient on standard triple immunosuppressive therapy showed a modest decrease in virgin-naïve (Bm2) B-cells post-transplant accompanied with an increase in memory-like B cells [55] . This was accompanied by a rapid and long-lasting decline in Bm2' or transitional B cells after transplantation, which has subsequently been confirmed by an independent study [42] . Even less is known about the peripheral B cell subset distribution upon rejection. Van 
Regulatory B cells and solid organ transplantation
Paradoxically, B cells and plasma cells have recently been described as being able to regulate immune responses [58, 59] . Original findings on the capacity of B cells to regulate came from the field of autoimmunity. For example, when B cell deficient mice were used in the EAE model for multiple sclerosis, disease was still induced, but unlike wild type mice, knockout mice did not go into remission [60] . This indicated that B cells could potentially be involved in immune modulation, secondary to immune activation. Later, it was shown that B cell mediated regulation in this setting was IL-10 dependent [61] .
Up to date, regulatory B cells (Breg) remain a difficult to define population of cells, since the only definite marker at the moment is their capacity to produce IL-10. No master transcriptional regulator, or exclusive phenotype has been described yet. However, there are some phenotypes known in which Breg are enriched. In mice, a phenotype-independent marker for Breg appears to be TIM-1, which strongly enriches for Breg [62, 63] . Another B cell population with regulatory properties has been called B10, according to its production of IL-10 [64] . In mice, these cells are enriched in the CD1d hi CD5 + B cell population [65] , whereas in humans these cells are enriched in a memory-like pool of CD27 + CD24 hi B cells [66] . A second population of human Breg is enriched in the transitional B cell pool of CD24 hi CD38 hi B cells [67, 68] . Interestingly, it has recently been shown that the immunoregulatory cytokines IL-10 and IL-35 could also be produced by CD138 + plasma cells [69] , extending the range of B cells capable of regulating immune responses even more.
In transplantation, the notion that B cells may have regulatory properties is a rather new concept.
There are a limited number of experimental animal studies that underpin the possibility that Breg may be important for tolerance induction. For TIM-1 + B cells, it has been shown that stimulation with a low affinity anti-TIM-1 antibody resulted in prolonged graft survival in a mouse model of islet transplantation [62] . In concert with these findings, Lee et al. showed that combined anti-CD45RB and anti-TIM-1 treatment resulted in 100% long-term islet allograft survival [70] . The prolonged graft survival was dependent on the presence of IL-10 producing B cells. The same group recently showed that Breg require the presence of regulatory T cells (Treg) to establish tolerance, and that the interaction between Breg and Treg is possibly dependent on TGFβ [71] .
Using a mouse model of cardiac transplant tolerance, Le Texier et al. showed that B cells in tolerant animals were blocked in their progression from IgM to IgG, as well as being negative for the memory marker CD27 [72] , which is in line with evidence showing that immature B cells have immunoregulatory properties [67] .
Clinical evidence for a role of B cells in renal tolerance induction and/or maintenance has also been published [73] . A major breakthrough in this field was when two independent consortium studies on biomarkers of operational tolerance in renal transplant recipients both showed a clear B cell dominated fingerprint of tolerance [27, 28] . In separate studies, operationally tolerance was associated with increased levels of peripheral B cells, with increased numbers of naïve and transitional B cells [27, 28, 74, 75] , as well as memory B cells [76] , compared to stable renal transplant recipients under immunosuppressive drugs. While operational tolerance showed a different B cell subset distribution compared to stable patients, it was similar to healthy non-transplanted individuals.
There are little functional data on B cell regulation in humans. However, when transitional B cells were polyclonally activated, there was a tendency to higher frequencies of IL-10 producing cells in operationally tolerant individuals [27] . In concordance with these findings, increased IL-10 production in total B cells of tolerant individuals has also been observed by the Nantes group [75] .
In addition to phenotypic data, gene expression analysis revealed that MS4A1 (CD20) levels in urine were elevated in tolerant patients, whereas the peripheral blood gene expression profile was characterized by high expression of several B cell-related genes. Two studies have since shown that the most differentially expressed genes, elevated during tolerance (MS4A1, CD79B and TCL1A), were expressed at low levels in patients with acute rejection [42, 77] . These findings indicate that MS4A1, CD79B and TCL1A may be markers for immune activation/regulation.
The relative role of B cells to tolerance induction and or maintenance is subject of intense research. With a better understanding on the regulatory capacities and pathways of B cells, targeted therapy to induce regulation may be possible in the future.
Evaluating B cell functionality
Currently, the few above-mentioned studies on B cell immunophenotyping have not proven to identify patients with a clear risk profile for rejection. The transplant community searches for assays that may predict clinical events in solid-organ transplant recipients with high specificity. As such, detecting
antigen-specific immune cells may allow to do so. Therefore, there has been increasing interest in developing strategies to track donor antigen-reactive B cells. This approach may be useful to improve understanding of anti-donor memory responses and should help to get better diagnostic and treatment options in transplant recipients [78] . Studies on HLA-specific B cells are evolving from evaluating the ability of B cells to produce HLA antibodies in vitro to quantifying HLA-specific B cells by flow cytometry and ELISPOT.
In vitro assays to evaluate B cell production of HLA specific antibodies
Activation of B cells is a multistep process, which starts with B cell recognition of its cognate antigen, and leads to the formation of short-lived plasmablasts and, in case of germinal center formation, long-lived plasma cells and memory B cells. In the 90's some research groups were able to grow B cells in culture and differentiate them into plasma cells [79] [80] [81] . Other groups had demonstrated the ability to detect and measure precursor frequencies of antibody secreting B lymphocytes specific for several antigens, such as A or B antigens in individuals with different blood groups, rheumatoid factor in patients with rheumatoid arthritis or antigens from Plasmodium falciparum in patients with malaria in limiting dilution format cultures [82, 83] .
Analysis of IgG antibody specificities in supernatants of B cells that are activated in a polyclonal fashion, not leading to in vitro class switching, provides information on the composition of the preexisting memory B cell compartment. In the setting of transplantation, Mulder and colleagues were the first to describe an assay activating B cells in vitro and analyzing their HLA antibody secreting capacity [84] . They were able to calculate the precursor frequency of B-cells with HLA specificity by measuring HLA antibodies in the supernatants of limiting dilution B cell cultures. These studies permitted them to dissect the specificities of circulating B cells in patients, as well as to study the correlation with serum antibodies.
More recently, Han and colleagues used purified B cells from allograft recipients, sensitized patients or multiparous women and cultured them with polyclonal stimulation to obtain supernatants for studying HLA antibody specificities with Luminex. Interestingly, they found that donor-specific antibodies were sometimes produced in B-cell cultures when circulating HLA antibodies were negative [85] . Using a similar approach, Snanoudj and colleagues tested the presence of circulating alloreactive memory B cells in 69 patients with end-stage renal disease under renal replacement therapy.
They showed HLA-specific memory B cells in patients with serum HLA antibodies following multiple HLA-immunizing events. In other patients, serum HLA antibodies were not associated with the detection of specific memory B cells [86] . In concordance with the study of Han et al., some specificities found in the culture supernatant were not detected in the accompanying serum sample, indicating that memory B cells may be present in the absence of antibody production.
Flow cytometry based assays for HLA specific B-cell quantification
Besides phenotypic characterization, flow cytometry has also been used with the intention to quantify the peripheral HLA-specific B-cell compartment. The Leiden group was able to quantify HLAspecific B cells by flow cytometry, staining CD19 + B-cells with HLA tetramers (HLA antigens) without pre-culturing those B-cells [87] . Using developed human B hybridomas specific for HLA molecules, they proved that tetrameric HLA-A2 provided a suitable affinity ligand for isolation of allospecific B cells. Tetramer technology for the detection of HLA-specific B cells is a convenient method, but suffers from the presence of B cells that can recognize streptavidin-biotin or the fluorochrome, both of which are part of the HLA tetramer complex. [91, 92] Pre-incubation of B cells with streptavidin-biotin [87] and/or the use of multiple tetramers coupled to different fluorochromes [93] can be used to overcome these problems.
Toward ELISPOT
The ELISPOT assay was originally developed as a modification of ELISA techniques to detect antigen-specific antibody-secreting B cells [94] . It is a solid-phase enzyme-linked immunosorbent assay designed for enumeration of cells secreting specific antibodies. It employs B cells from immunized animals or humans, which are incubated in antigen-coated polystyrene plates (the antigen of interest).
After removal of the cells, bound secreted antibodies are visualized by means of an immunoenzyme procedure. Spots form where antibody production has occurred and can be enumerated to establish a frequency of antigen-specific B cells. ELISPOT has been adapted for various purposes, especially to identify and enumerate cells able to produce cytokines. The high sensitivity of the assay could be useful for detecting low-frequency HLA-specific B-cells.
The group of Mayo Clinic published the first report of a B cell ELISPOT applied to evaluate HLA antibody producing cells in 2008 [95] . They selected the CD138 + plasma cell fraction of the bone marrow for the assay, which mainly expressed the long-lived PC phenotype (CD138 + , CD38
The correlation between serum alloantibody and plasma cell alloantibody specificity was generally high.
However, the correlation between allospecific plasma cell frequency in the bone marrow and serum alloantibody levels measured by the single antigen flow bead assay was poor. The investigators did not find that pretransplant treatment with plasma-exchange, intravenous immunoglobulin or polyclonal rabbit antithymocyte globulin had an effect on the number of HLA antibody producing plasma cells or alloantibody production. The need of an invasive procedure to obtain bone marrow samples has limited this approach.
In contrast, the Leiden group developed an ELISPOT assay using peripheral blood B-cells, which is a more realistic source for an assay to monitor patients. Working with B-cells poses an additional challenge, since they require in vitro pre-activation, as described above. Nevertheless, the group developed an assay that allowed for determining the frequency of HLA class I-specific memory B-cells from peripheral blood [96] . Monomeric HLA class I molecules were used as antigen in the ELISPOT plates (Fig. 4, left panel) . Exceptional validation of the technique was possible for the availability of Bcell hybridomas, which produce antibodies toward defined HLA molecules [97] . They reported on the detection of HLA-specific B-cells in pregnancy-immunized individuals and in immunized kidney transplant recipients. Recently, the same group has developed a similar assay for the detection of HLA class II specific memory B cells [98] . Analogous to the HLA class I assay, this technique uses monomeric HLA class II molecules for the detection of HLA-specific memory B cells (Fig. 4, right panel) . This HLA class II specific memory B cell ELISPOT assay may be of great clinical interest, since HLA class II molecules are predominantly implicated in chronic antibody-mediated rejection [10, 11, 29, 99] . 
Summary
The 
